现对股骨头坏死的治疗方法种种，细胞移植是最新且具有潜力的方法但临床效果均不尽完善，要达到更好的治疗效果必须要从分子水平提高坏死区修复速度。最新的研究报道miRNA-214的靶基因是Atf4或Osterix，两者是对成骨细胞分化和骨形成至关重要的因子。结合我们的预实验结果提示着：miRNA-214可能在ONFH早期骨修复阶段发挥作用，也可能是ONFH治疗中的一个潜在策略。.我们分别构建miRNA-214激动剂和miRNA-214拮抗剂处理BMSCs细胞，检测miRNA-214对成骨特异性标记物的影响；动物模型体内试验考察Bio-oss骨粉联合处理后的BMSCs细胞移植对骨组织修复的效果；分别构建Atf4和Osterix的野生型和突变型荧光素酶报告质粒，转染入细胞进行双荧光素酶报告分析检测miRNA-214在ONFH的靶基因。本课题将为治疗ONFH提供有力的实验依据。

Recently reports showed that transplanting is new potential therapy for curing early-stage osteonecrosis of the femoral head(ONFH). However, it still exist many disadvantages. In order to get better therapeutic effect, it is necessary to enhance the bone turnover in the osteonecrosis area. The newest research reported that the target gene of miRNA-214 is Atf4 or Osterix, which are the crucial factor for the osteoblast differentiation and bone formation. Accordingly, we speculate that miRNA-214 may play an important role at early stage of bone repair, or is a potential strategy in ONFH treatment. .We will treat cells using miRNA-214 agonist and miRNA-214 antagonist respectively, then measure the influence of miRNA-214 to the specific markers of osteoblast differentiation; analysis the effect of miRNA-214 in the co-therapy of Bio-oss and BMSCs in early-stage osteonecrosis of the femoral head animal model; we will also transfect cells with Atf4 or Osterix luciferase plasmid to measure the target gene in ONFH. We investigate the function of miRNA-214 in the co-therapy of Bio-oss and BMSCs in early-stage osteonecrosis of the femoral head. This should be significant for treating of ONFH..